# BioNexus Gene Lab Corp: Form 10-K for the period ended Dec 31, 2021

- Company: [BioNexus Gene Lab Corp](/companies/bglc.md) (CIK 1737523)
- Form: 10-K
- Filed: 2022-04-06
- Accepted by EDGAR: Apr 6, 2022, 12:16 ET
- Period: 2021-12-31
- Accession: 0001477932-22-002089
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $13.4m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | $11.2m | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2021-01-01 to 2021-12-31 | $2.2m | us-gaap:GrossProfit |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | $1.1m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | $751.6k | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | $9.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $3.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-12-31 | $2.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $7.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $9.6m | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $2.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $2.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-12-31 | $7.2m | us-gaap:StockholdersEquity |

## Business

As filed, 40,974 characters.

BIONEXUS GENE LAB CORP.

### CONSOLIDATED BALANCE SHEETS

### AS OF DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

| STOCKHOLDERS’ EQUITY | Note | As of December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: | ---: |
| As at December 31, 2021, common stock, no par value; 300,000,000 shares authorized and 171,218,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2020, common stock, no par value; 300,000,000 shares authorized and 171,218,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. | 11 | $10,779,574 | $10,779,574 |
| Additional paid in capital |  | (5,011,891) | (5,011,891) |
| Accumulated surplus |  | 1,512,358 | 760,787 |
| Other comprehensive (losses)/income |  | (100,262) | 133,684 |
| TOTAL STOCKHOLDERS’ EQUITY |  | 7,179,779 | 6,662,154 |
| **TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY** |  | $9,574,390 | $10,115,293 |

See accompanying notes to the consolidated financial statements.

F-4

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

|  | Year ended December 31, 2021 | 2020 |
| --- | ---: | ---: |
| REVENUE | $13,362,567 | $11,390,440 |
| COST OF REVENUE | (11,168,747) | (9,670,617) |
| GROSS PROFIT | 2,193,820 | 1,719,823 |
| OTHER INCOME | 66,491 | 886,942 |
| OPERATING EXPENSES |  |  |
| General and administrative | (1,204,484) | (1,332,943) |
| **PROFIT FROM OPERATIONS** | **1,055,827** | **1,273,822** |
| FINANCE COSTS | (12,973) | (11,313)) |
| **PROFIT BEFORE TAX** | **1,042,854** | **1,262,509** |
| Tax expense: |  |  |
| Deferred tax | (26,736) | 1,238 |
| Income tax | (264,547) | (169,649) |
| Total tax expense | (291,283) | (168,411) |
| **NET PROFIT** | **$751,571** | $1,094,098 |
| Other comprehensive income: |  |  |
| Foreign currency translation (loss)/gain | (233,946) | 150,787 |
| **COMPREHENSIVE INCOME** | **$517,625** | $1,244,885 |
| Earnings per share - Basic and diluted | 0.003 | 0.012 |
| Weighted average number of common shares outstanding – Basic and diluted | 171,218,152 | 102,918,015 |

See accompanying notes to the consolidated financial statements.

F-5

#### Table of Contents

### BIONEXUS GENE LAB CORP

### CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

|  | Common stock Number of shares | Amount | Additional paid in capital | Accumulated surplus/(loss) | Accumulated other comprehensive income/ (loss) | Total Equity |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| **Balance as of January 1, 2020** | 102,730,891 | $6,484,669 | $(5,011,891) | $(333,311) | $(17,103) | $1,122,364 |
| Issuance of shares | 68,487,261 | 4,294,905 | - | - | - | 4,294,905 |
| Net profit for the year | - | - | - | 1,094,098 | - | 1,094,098 |
| Foreign currency translation gain | - | - | - | - | 150,787 | 150,787 |
| **Balance as of December 31, 2020** | **171,218,152** | **$10,779,574** | **$(5,011,891)** | **$760,787** | **$133,684** | **$6,662,154** |
| Net profit for the year | - | - | - | 751,571 | - | 751,571 |
| Foreign currency translation loss | - | - | - | - | (233,946) | (233,946) |
| **Balance as of December 31, 2021** | **171,218,152** | **$10,779,574** | **$(5,011,891)** | **$1,512,358** | **$(100,262)** | **$7,179,779** |

See accompanying notes to the consolidated financial statements.

F-6

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### CONSOLIDATED STATEMENT OF CASH FLOWS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

| Cash flows from operating activities: | Year Ended December 31, 2021 | 2020 |
| --- | ---: | ---: |
| Net profit | $751,571 | $1,094,098 |
| Adjustments to reconcile net profit to net cash generated from operating activities: |  |  |
| Amortization of right of use asset | 16,933 | 10,816 |
| Bad debts | 3,809 | 2,658 |
| Depreciation of property, plant and equipment | 91,282 | 90,787 |
| Dividend income | (22,036) | (6,310) |
| Fair value gain on other investments | 29,850 | (38,742) |
| Loss on disposal of other investments | - | 3,965 |
| Gain on disposal of property, plant and equipment | - | (706,953) |
| Operating profit before working capital changes | 871,409 | 450,319 |
| Changes in operating assets and liabilities: |  |  |
| Inventories | (345,745) | 147,038 |
| Trade and other receivables | 579,217 | 411,069 |
| Deferred cost of revenue | (67,606) | - |
| Trade and other payables | (1,180,535) | (524,240) |
| Advance payment from customer | 30,307 | - |
| Deferred revenue | 77,276 | - |
| Operating lease liabilities | (20,169) | 38,931 |
| Tax recoverable | 65,007 | 29,563 |
| Cash generated from operating activities | 9,161 | 552,680 |
| Cash flows from investing activities: |  |  |
| Acquisition of other investment | (515,840) | (108,631) |
| Dividend income | 22,036 | 6,310 |
| Net cash from acquisition of business under common control | - | 346,008 |
| Purchase of plant and equipment | (3,162) | (421,621) |
| Proceeds from disposal of other investments | 6,392 | 30,059 |
| Proceeds from disposal of property, plant and equipment | - | 1,467,865 |
| Net cash (used in)/generated from investing activities | (490,574) | 1,319,990 |
| Cash flows from financing activities: |  |  |
| Repayment of finance lease | (26,302) | (4,947) |
| Repayments to directors | (1,920) | - |
| Net cash used in financing activities | (28,222) | (4,947) |
| Foreign currency translation adjustment | (154,138) | 60,893 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (663,773) | 1,928,616 |
| CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR | 2,787,692 | 859,076 |
| **CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR** | **$2,123,919** | **$2,787,692** |

F-7

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### CONSOLIDATED STATEMENT OF CASH FLOWS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))(CONT’D)

### (Audited)

| CASH AND CASH EQUIVALENTS INFORMATION: |  |  |
| --- | ---: | ---: |
| Fixed deposits placed with financial institutions | $1,545,408 | $2,088,107 |
| Cash and bank balances | 578,511 | 699,585 |
| Cash and cash equivalents, end of financial year | 2,123,919 | 2,787,692 |
| Supplementary cash flow information: |  |  |
| Interest paid | $(12,973) | $(11,313) |
| Income tax refunded | - | 11,697 |
| Income tax paid | (226,770) | (143,496) |

See accompanying notes to the consolidated financial statements.

F-8

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND

BioNexus Gene Lab Corp. was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all of the outstanding capital stock of BGS Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 which it then subsequently changed its name to Bionexus Gene Lab Sdn. Bhd.

The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.

On December 31, 2021, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all of the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company.

The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.

The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period.

The corporate structure as at December 31, 2021 is depicted below:

|  |  |
| --- | --- |
| BioNexus Gene Lab Corp. a Wyoming company |  |
| 100% owned | 100% owned |
| Bionexus Gene Lab Sdn. Bhd., a Malaysian company | Chemrex Corporation Sdn. Bhd., a Malaysian Company |

F-9

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

☐ Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

☐ Basis of consolidation

The consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

☐ Use of estimates

In preparing these consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

☐ Cash and cash equivalents

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

☐ Trade receivables

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for expected credit losses on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

☐ Inventories

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income.

F-10

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

☐ Leases

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases, which was subsequently amended in 2018 by ASU 2018-10, ASU 2018-11 and ASU 2018-20 (collectively, Topic 842). Topic 842 will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. Topic 842 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. Topic 842 allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods.

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

☐ Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows:

| Categories | Principal Annual Rates |
| --- | ---: |
| Air conditioner | 20% |
| Buildings | 2% |
| Computer and software | 33% |
| Equipment | 20% |
| Furniture and fittings | 10% to 20% |
| Lab Equipment | 10% |
| Motor vehicle | 10% to 20% |
| Office equipment | 20% |
| Renovation | 10% to 20% |
| Signboard | 10% |

Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

F-11

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

☐ Impairment of long-lived assets

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

☐ Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

- identify the contract with a customer;
- identify the performance obligations in the contract;
- determine the transaction price;
- allocate the transaction price to performance obligations in the contract; and
- recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

☐ Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping ang handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

☐ Comprehensive income

ASC Topic 220, “*Comprehensive Income”* establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

F-12

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

☐ Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “*Income Taxes” (“*ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

☐ Net earnings or loss per share

The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “*Earnings per share”*. Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

☐ Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$ as being the primary currency of the economic environment in which the Company operates. The functional currency of the subsidiaries is Malaysian Ringgit (“MYR”) as being the primary currency of the economic environment in which the subsidiaries operate.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “*Translation of Financial Statement”*, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income.

F-13

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective years:

|  | December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Year-end US$1.00: MYR exchange rate | 4.1650 | 4.0170 |
|  | **January 1, 2021 to December 31, 2021** | **January 1, 2020 to December 31, 2020** |
| Yearly average US$1.00: MYR exchange rate | 4.1456 | 4.2010 |

☐ Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

☐ Fair value of financial instruments

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments

The Company also follows the guidance of the ASC Topic 820-10, “*Fair Value Measurements and Disclosures”* ("ASC 820-10"), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

- *Level 1* : Observable inputs such as quoted prices in active markets;
- *Level 2* : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
- *Level 3* : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

As of December 31, 2021, and December 31, 2020, the Company did not have any non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

☐ Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

F-14

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 4 – TRADE RECEIVABLES

The Company has performed an analysis on all its trade receivables and determined that all amounts are collectible by the Company. As such, trade receivables are reflected as a current asset and no allowance for expected credit loss has been recorded as of December 31, 2021 and December 31, 2020. Total of $3,809 and $2,658 of bad debts were written off for the year ended December 31, 2021 and December 31, 2020, respectively. The Company’s trade receivables consist of receivable from customers which are unrelated to the Company. The account receivables are non-interest bearing and is generally on 30 days to 90 days term.

### NOTE 5 – INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statements and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. It also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

BioNexus Malaysia and Chemrex are both subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range is 24% on its assessable income. Under the amendment of Income Tax Act 1967 by the Finance Act 2020 and with effect from year of assessment 2020, companies with paid-up capital of MYR2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to MYR600,000 (2020: MYR600,000) except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income.

| Tax Recoverable | As of December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Local | $- | $- |
| Foreign, representing Malaysia | - | (2,190) |
| Tax Recoverable | - | (2,190) |
| Income tax liabilities: |  |  |
| Local | - | - |
| Foreign, representing Malaysia | 97,585 | 61,313 |
| Income tax liabilities | 97,585 | 61,313 |
| Deferred tax liabilities: |  |  |
| Local | - | - |
| Foreign, representing Malaysia | 28,416 | 1,872 |
| Deferred tax liabilities | 28,416 | 1,872 |
| Total | $126,001 | $60,995 |

F-15

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 6 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES

Lease liabilities are measured at present value of the sum of remaining rental payment as of recognition with discount rate of 5.40% per annum adopted from Malayan Banking (Maybank) Berhad's base rate as a reference for discount rate, as this bank is the largest bank and national bank of Malaysia.

A single lease cost is recognized over the lease term on a generally straight-line basis. All cash payments of operating lease cost are classified within operating activities in the statement of cash flows.

As of December 31, 2021 and 2020 operating lease right of use assets as follows:

|  | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| Balance as of December 31, 2020 | $62,529 | $23,542 |
| Add: Addition of right of use assets | - | 61,128 |
| Reduction due to discount on rental | (913) | - |
| Less: accumulated amortization | (18,305) | (22,587) |
| Foreign translation differences | (2,221) | 446 |
| Balance as of December 31, 2021 | $41,090 | $62,529 |

As of December 31, 2021 and 2020 operating lease liabilities as follows:

|  | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| Balance as of beginning of the year | $63,079 | $24,148 |
| Add: Addition of lease liabilities | - | 61,128 |
| Less: Discount on rental | (972) | - |
| Less: gross repayment | (16,856) | (26,036) |
| Add: imputed interest | 2,704 | 3,380 |
| Foreign translation differences | (5,046) | 459 |
| Balance as of end of the year | 42,909 | 63,079 |
| Less: lease liabilities current portion | (18,272) | (20,702) |
| Lease liabilities non-current portion | $24,637 | $42,377 |

As of December 31, 2021 and 2020, the maturities of the operating lease obligation are as follows:

| Years ending December 31: | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| 2021 | $- | $20,702 |
| 2022 | 18,272 | 18,945 |
| 2023 | 11,987 | 12,428 |
| 2024 | 12,650 | 11,004 |
| Total | $42,909 | $63,079 |
| The amortization of the operating lease right of use asset for the year ended December 31, 2021 and 2020 were $16,933 and $10,816, respectively. |  |  |

F-16

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

Other information:

| Cash paid for amounts included in the measurement of lease liabilities: | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| Operating cash flow from operating leases | $(20,169) | $38,931 |
| Right of use assets obtained in exchange for operating lease liabilities | 41,090 | 65,529 |
| Remaining lease term for operating leases (years) | 2 | 4 |
| Weighted average discount rate for operating leases | $5.40% | $5.40% |

Lease expenses for the year ended December 31, 2021 and 2020 were $2,704 and $3,380 respectively.

### NOTE 7 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

|  | As of December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Air conditioner | $1,124 | $1,124 |
| Computer and software | 1,814 | 1,371 |
| Equipment | 43,010 | 42,830 |
| Furniture and fittings | 86,961 | 86,961 |
| Lab equipment | 284,822 | 284,822 |
| Land and buildings | 1,506,969 | 1,506,969 |
| Motor vehicle | 137,914 | 137,914 |
| Office equipment | 37,700 | 35,160 |
| Renovation | 107,414 | 107,414 |
| Signboard | 704 | 704 |
|  | 2,208,432 | 2,205,269 |
| (Less): Accumulated depreciation | (525,631) | (441,541) |
| Add: Foreign translation differences | (48,383) | 21,874 |
| Property, plant and equipment, net | $1,634,418 | $1,785,602 |

During the year ended December 31, 2021 and 2020, the Company recorded depreciation of $91,282 and $90,787, respectively.

F-17

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 8 – OTHER INVESTMENTS

|  | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| As of beginning of the year | $281,668 | $12,215 |
| Acquisition of business under common control | - | 147,882 |
| Addition during the year | 515,840 | 108,631 |
| Disposal during the year | (6,392) | (34,923) |
| Fair value gain | (29,850) | 38,742 |
| Foreign exchange translation | (12,239) | 9,121 |
| As of end of the year | $749,027 | $281,668 |

The other investments consists of the following shares:

| Investment in quoted shares: | As of December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Malaysia | 590,788 | 279,724 |
| Singapore | 97,780 | - |
| Hong Kong | 58,584 | - |
|  | $747,152 | $279,724 |
| Investment in unquoted shares: |  |  |
| Malaysia | 1,875 | 1,944 |
|  | $749,027 | $281,668 |

### NOTE 9 – TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

### NOTE 10 – FINANCE LEASE

The Company purchased motor vehicles under finance lease agreements with the effective interest rate 5.70% of per annum, with principal and interest payable monthly. The obligations under the finance lease are as follows:

|  | As of December 31, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Finance lease | $35,254 | $63,703 |
| Less: interest expense | (1,216) | (3,363) |
| Net present value of finance lease | 34,038 | 60,340 |
| Current portion | 21,235 | 25,048 |
| Non-current portion | 12,803 | 35,292 |
| Total | $34,038 | $60,340 |

F-18

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

As of December 31, 2021 and 2020, the maturities of the finance lease obligations are as follows:

| Years ending December 31: | As of December 31, 2021 | As of December 31, 2020 |
| --- | ---: | ---: |
| 2021 | $- | $25,048 |
| 2022 | 21,235 | 22,017 |
| 2023 and after | 12,803 | 13,275 |
| Total | $34,038. | $60,340 |

### NOTE 11 – CONCENTRATION OF RISKS

a) Major customers

There are no major customers who accounted for 10% or more of the Company’s revenue for the financial year ended December 31, 2021 and 2020.

b) Major suppliers

For year ended December 31, 2021, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:

|  | 2021 Purchase | 2020 | 2021 Percentage of purchases | 2020 | 2021 Accounts payable trade | 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Vendor A | $2,026,842 | $2,090,090 | 18.17% | 21.61% | $640,827 | $1,031,417 |
| Vendor B | $1,815,817 | $1,319,232 | 16.28% | 13.64% | $397,636 | $335,215 |
| Vendor C | $1,404,442 | $860,177 | 12.59% | 8.89% | $405,999 | $249,429 |
| Vendor D | $1,191,344 | $1,350,069 | 10.68% | 13.96% | $269,966 | $572,938 |
|  | $6,438,445 | $5,619,568 | 57.72% | 58.10% | $1,714,428 | $2,188,999 |

### NOTE 12– STOCKHOLDERS’ EQUITY

As at December 31, 2021 and 2020, the Company issued and outstanding, common stock is 171,218,152 and 171,218,152 shares respectively.

F-19

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

### NOTE 13 – SEGMENTED INFORMATION

At December 31, 2021, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

|  |  |
| --- | --- |
| BioNexus Gene Lab Corp. a Wyoming company |  |
| 100% owned | 100% owned |
| Bionexus Gene Lab Sdn. Bhd., a Malaysian company | Chemrex Corporation Sdn. Bhd., a Malaysian company |

For year ended December 31, 2021, segmented revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

|  | BioNexus Malaysia Year ended December 31, 2021 | Chemrex | BGLC | Total |
| --- | ---: | ---: | ---: | ---: |
| REVENUE | $1,515,673 | $11,846,894 | $- | $13,362,567 |
| COST OF REVENUE | (1,126,059) | (10,042,688) | - | (11,168,747) |
| GROSS PROFIT | 389,614 | 1,804,206 | - | 2,193,820 |
| OTHER INCOME | 7,467 | 59,024 | - | 66,491 |
| OPERATING EXPENSES |  |  |  |  |
| General and administrative | (86,973) | (989,617) | (127,894) | (1,204,484) |
| FINANCE COSTS | (4,158) | (8,815) | - | (12,973) |
| **PROFIT/(LOSS) BEFORE TAX** | **305,950** | **864,798** | **(127,894)** | **1,042,854** |
| Tax expense: |  |  |  |  |
| Deferred tax | (11,997) | (14,739) |  | (26,736) |
| Income tax | (30,482) | (234,065) |  | (264,547) |
| Total tax expense | (42,479) | (248,804) | - | (291,283) |
| **NET PROFIT/(LOSS)** | **$263,471** | **$615,994** | **$(127,894)** | **$751,571** |

F-20

#### Table of Contents

### BIONEXUS GENE LAB CORP.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020

### (Currency expressed in United States Dollars (“US$”))

### (Audited)

|  | BioNexus Malaysia Year ended December 31, 2020 | Chemrex | BGLC | Total |
| --- | ---: | ---: | ---: | ---: |
| REVENUE | $134,095 | $11,256,345 | $- | $11,390,440 |
| COST OF REVENUE | (113,042) | (9,557,576) | - | (9,670,617) |
| **GROSS PROFIT** | **21,053** | **1,698,769** | **-** | **1,719,823** |
| OTHER INCOME | 13,148 | 873,793 | 0 | 886,942 |
| OPERATING EXPENSES |  |  |  |  |
| General and administrative | (88,789) | (1,107,002) | (137,152) | (1,332,943) |
| FINANCE COSTS | (2,482) | (8,831) | - | (11,313) |
| **PROFIT/(LOSS) BEFORE TAX** | **(57,070)** | **1,456,729** | **(137,150)** | **1,262,509** |
| Tax expense: |  |  |  |  |
| Deferred tax | - | 1,238 | - | 1,238 |
| Income tax | (881) | (168,768) | - | (169,649) |
| Total tax expense | (881) | (167,530) | - | (168,411) |
| **NET PROFIT/(LOSS)** | **$(57,951)** | **$1,289,199** | **$(137,150)** | **$1,094,098** |

|  | As of December 31, 2021 and 2020 Total Assets 2021 | 2020 | Total Liabilities 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| BGLC & Bionexus | $1,167,214 | $1,107,048 | $121,586 | $169,325 |
| Chemrex | 8,407,176 | 9,008,245 | 2,273,025 | 3,283,814 |
| TOTAL | 9,574,390 | 10,115,293 | 2,394,611 | 3,453,139 |

F-21

#### Table of Contents

### NOTE 14 – SIGNIFICANT EVENTS

a) Acquisition of business under common control

During the financial year, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd., pursuant to a Share Exchange Agreement. The transfer of net assets was completed on 31 December 2020.

b) Covid-19 pandemic outbreak

On 11 March 2020, the World Health Organization declared the Coronavirus (“Covid-19”) outbreak to be a pandemic, which has caused severe global social and economic disruptions and uncertainties, including markets where the Company operates or intends to operate. The Company is actively monitoring and managing its operations to respond to these changes, the Company does not consider it practicable to provide any quantitative estimate on the potential impact it may have on the Company as the outbreak continue to evolve as of the date of this report.

### NOTE 15 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after December 31, 2021 up through March 24, 2022 of these consolidated financial statements. During the period, the Company did not have any material recognizable subsequent events.

F-22

## Risk factors

As filed, 43,012 characters.

### RISK FACTORS

An investment in our common stock involves a number of very significant risks. You should carefully consider the following known material risks and uncertainties in addition to other information in this Form 10-K in evaluating our company and its business before purchasing shares of our company’s common stock. You could lose all or part of your investment due to any of these risks.

14

#### Table of Contents

### Risk Factors Relating to Our Business

**BIONEXUS MALAYSIA HAS A LIMITED OPERATING HISTORY AND LIMITED BUSINESS GROWTH.** BioNexus Malaysia has been operational since April 2017; therefore, it has had limited operations which makes it difficult to evaluate its business and our prospects. In addition, to date, they have not experienced substantial growth in our business. The likelihood of its success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by a small operating company trying to expand its business enterprise and the highly competitive environment in which we will operate. Consequently, there can be no assurance that the business of BioNexus Malaysia will grow in the future. Moreover, because of its limited operating history, it is difficult to extrapolate any meaningful projections about its future.

**THE EFFICACY OF BIONEXUS MALAYSIA BLOOD SCREENING PROCESS HAS NOT SUPPORTED BY ANY INDEPENDENT STUDIES OR TESTS.** BioNexus Malaysia blood screening process, which was commercially launched in July 2017, has been developed by late Dr. Choong Chin Liew, our largest shareholder. Dr. Liew has spent many years developing and testing various aspects of his current protocols and has published numerous articles concerning his blood screening protocols. Nonetheless, these protocols and procedures have not been the subject of a wide scale independent study or studies proving the efficacy of our testing protocols.

As a result, it is conceivable, that despite Dr. Liew’s efforts, our current blood based genomic screening process may not be as efficacious as we believe, which in effect would yield false positive or false negative test results. Inaccurate test results in turn could lead to significant financial exposure to the Company. The exposure would arise from claims by patients for a misdiagnosis of current or perceived current medical conditions. Claims for a false positive diagnosis could include increased medical costs arising from more medical tests and physician examinations in response to the false positive diagnosis. Claims for false negative diagnosis could include claims for loss of life and pain and suffering arising from the failure to diagnose a current medical condition. While we inform patients that our diagnostics are merely one of many tools employed in a health care diagnoses, these claims could be substantial and cause a material adverse impact on our business.

**BIONEXUS MALAYSIA MAY FACE PRODUCT LIABILITY CLAIMS.** Due to the nature of our business, we may face claims for product liability. These claims may arise from the inaccurate or erroneous diagnosis of patient information or the mix-up of patient information whereby a patient receives the wrong diagnostic information. While we feel confident in our accuracy of our diagnostic analysis and the procedures which we have implemented to ensure the safeguard of patient information, we cannot provide assurances that product liability claims will arise in the future.

Moreover, litigation or adverse publicity resulting from these allegations could materially and adversely affect our business, regardless of whether the allegations are valid or whether we are liable. Currently we have no product liability insurance coverage, and even if there was such coverage, there would be no assurance that such coverage would be sufficient to properly protect us. Further, claims of this type, whether substantiated or not, may divert our financial and management resources from revenue generating activities and the business operation.

Presently, we do not have insurance to cover any product liability claims. This lack of insurance may cause a material adverse impact on the Company if product liability claims arise.

**INEFFECTIVE RISK MANAGEMENT POLICIES AND PROCEDURES.** The Company relies on a combination of technical and human factors to protect the Company against risks. Its policies, procedures and practices are used to identify, monitor and control a variety of risks, including risks related to human error and hardware and software errors. The administration and results of each test are reviewed by a physician and a scientist in Malaysia before the results are released to the patient. The Company’s standard of operations has been developed internally primarily by Dr. Liew. These risk-management methods may not adequately prevent losses and may not protect us against all risks, in which case our business, economic conditions, operations and cash flows may be materially adversely affected.

15

#### Table of Contents

We have risk-management policies, control systems and compliance manuals in place; however, there is no guarantee that such policies, systems, and manuals will be effectively applied in every circumstance by our staff for example; employees could override the system technology and theoretically waive requirements, thereby exposing our company to the risk of compromised test result.

**WE WILL NEED ADDITIONAL FINANCING IN ORDER TO GROW OUR BUSINESS.** We do not have significant assets with which to expand our business. We intend to expand our business through increased marketing efforts in Malaysia and elsewhere for both of our business line, the blood based genomic screening process and chemical distribution business. These additional expenditures are intended to be funded from cash on hand and, if necessary, third-party sources, including the incurring of debt and/or the sale of additional equity securities. In addition to requiring additional financing to fund expansion, the Company may require additional financing to fund working capital and operating losses in the future should the need arise. The incurrence of debt creates additional financial leverage and therefore an increase in the financial risk of the Company’s operations. The sale of additional equity securities will be dilutive to the interests of current equity holders. In addition, there can be no assurance that such additional financing, whether debt or equity, will be available to the Company or that it will be available on acceptable commercial terms. Any inability to secure such additional financing on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.

**AS WE UNDERTAKE BIONEXUS MALAYSIA’S BUSINESS, WE WILL BE SUBJECT TO COMPLIANCE WITH POTENTIAL GOVERNMENT REGULATION THAT MAY INCREASE IN THE FUTURE**. Currently, there are no governmental regulations that materially restrict our screening business. Pathology Laboratory Bill of 2007 (“Pathology Act”) has been passed by the Malaysian Parliament, however, since 2007, the government has not implemented the regulations underlying the legislation nor has the government enforced the Pathology Act. Any such regulations could establish criteria for the various classes and specialties of laboratories, the organization and management system of the laboratory, the qualification and experience of the person-in-charge, the qualification and competence of pathologists, scientific and technical staff engaged to conduct tests, and the standards of laboratory practice. We cannot predict whether we would be able to comply with the Pathology Act and its regulations, if implemented. In addition, there also is a risk that the regulations arising from the Pathology Act or new legislation or regulations could increase our costs of doing business or otherwise prevent us from carrying out the expansion of our business. Accordingly, our business may be harmed if we are no able to comply with any future governmental legislation or regulations, including the Pathology Act.

**OUR BLOOD BASED GENOMIC SCREENING PROCESS MAY NOT ACHIEVE COMMERCIAL SUCCESSES IN THE MARKETPLACE.** Our blood based genomic screening process may not be acceptable in the marketplace for a variety of factors. One factor may be that doctors and hospitals may be loathed to recommend our screening process as it may be deemed competitive to existing health care services that are offered by doctors and hospitals. Another factor may be that patients could be fearful of learning potentially negative health results and as a consequence, may not subscribe to our screening process. The occurrence of either of these factors may impact the successful reception of our product in the marketplace and negatively impair our further revenue potential.

**BUSINESS DISRUPTIONS COULD SERIOUSLY HARM OUR FUTURE REVENUE AND FINANCIAL CONDITION AND INCREASE OUR COSTS AND EXPENSES.** Our operations could be subject to power shortages, telecommunications failures, wildfires, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Unfavorable global economic conditions could adversely affect both of our business segments, financial condition, or results of operations.

We do not carry insurance for all categories of risk that our business may encounter. Although we intend to obtain some form of business interruption insurance in the future, there can be no assurance that we will secure adequate insurance coverage or that any such insurance coverage will be sufficient to protect our operations to significant potential liability in the future. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.

16

#### Table of Contents

**OUR SOFTWARE IS HIGHLY COMPLEX AND MAY CONTAIN UNDETECTED ERRORS.** Our proprietary software underlying our diagnosis is highly complex and may contain undetected errors or vulnerabilities, some of which may only be discovered after a diagnosis. This may result in an inaccurate diagnosis which could expose us to substantial liability due to the misdiagnosis. Any errors or vulnerabilities discovered in our software could result in damage to our reputation, loss of clients, loss of revenue or liability for damages, any of which could adversely affect our growth prospects and our business.

**WE MAY BE UNABLE TO PROTECT OUR INTELLECTUAL PROPERTY ADEQUATELY.** Our proprietary software is an essential asset of our business. To establish and protect our intellectual property rights, we rely primarily upon a trade secret, and to a lesser extent, contractual provisions with current and future employees. Further, our software is not patent protected nor is it copyrighted. Resultantly, our efforts to protect our intellectual property may not be sufficient or effective. If these measures do not protect our intellectual property rights, third parties could use the Company’s technology, and its ability to compete in the market would be reduced significantly.

In addition, we may not be effective in policing unauthorized use of our intellectual property. Even if we do detect violations, we may need to engage in litigation to enforce our intellectual property rights. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive and could divert our management’s attention. In addition, our efforts may be met with defenses and counterclaims challenging the validity and enforceability of our intellectual property rights or may result in a court determining that our intellectual property rights are unenforceable. If we are unable to cost-effectively protect our intellectual property rights, then our business could be harmed.

**WE MAY BE SUBJECT TO INTELLECTUAL PROPERTY CLAIMS, WHICH ARE EXTREMELY COSTLY TO DEFEND, COULD REQUIRE US TO PAY SIGNIFICANT DAMAGES AND COULD LIMIT OUR ABILITY TO USE CERTAIN TECHNOLOGIES IN THE FUTURE.** Companies in bio-medical or bio-technology industries are frequently subject to litigation based on allegations of infringement or other violations of intellectual property rights. To the extent we gain greater public recognition, we may face a higher risk of being the subject of intellectual property claims. Third-party intellectual property rights may cover significant aspects of our technologies or business methods or block us from expanding our offerings. Any intellectual property claims against us, with or without merit, could be time consuming and expensive to settle or litigate and could divert the attention of our management. Litigation regarding intellectual property rights is inherently uncertain due to the complex issues involved, and we may not be successful in defending ourselves in such matters.

In addition, some of our competitors have extensive portfolios of issued patents. Many potential litigants, including some of our competitors and patent holding companies, have the ability to dedicate substantial resources to enforcing their intellectual property rights. Any claims successfully brought against us could subject us to significant liability for damages and we may be required to stop using technology or other intellectual property alleged to be in violation of a third party’s rights. We also might be required to seek a license for third-party intellectual property. Even if a license is available, we could be required to pay significant royalties or submit to unreasonable terms, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant time and expense. If we cannot license or develop technology for any allegedly infringing aspect of our business, we would be forced to limit our service and may be unable to compete effectively. Any of these results could harm our business.

**WE FACE COMPETITION FROM OTHER LABORATORIES AND OUR OPERATING RESULTS WILL SUFFER IF WE FAIL TO COMPETE EFFECTIVELY.** We believe there are a limited number of companies worldwide that specialize in RNA blood analysis to detect disease. However, there are a few laboratories in universities and research institutions that are attempting to extend their researches from DNA into RNA screening. If they have some breakthrough and they could be our potential competitors. Many of our potential competitors may have strong financial and resources, such as sophisticated research capabilities and development staff than we do. Their discovery and development of novel protocol that could make our genomic screening obsolete even though with FDA and European Union certification. As a result of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing screening process for the cancer, inflammation, osteoarthritis and many more indications.

17

#### Table of Contents

In addition, smaller or early-stage companies also may prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target disease areas.

If our competitors market products that are more effective, safer or less expensive or that reach the market sooner than our future products, if any, we may not achieve commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.

**WE ALSO FACE COMPETITION FROM OTHER CHEMICAL DISTRIBUTORS AND OUR OPERATING RESULTS WILL SUFFER IF WE FAIL TO COMPETE EFFECTIVELY.** We believe there are a limited number of companies in Malaysia that provide the broad range of chemicals that we provide to customers. Many of our existing and potential competitors may have stronger financial, product development and marketing capabilities than our existing capabilities. As a result of these factors, our competitors may succeed in attracting new customers which we may need to further develop our business.

**WE MAY INCUR SIGNIFICANT COSTS TO BE A PUBLIC COMPANY TO ENSURE COMPLIANCE WITH U.S. CORPORATE GOVERNANCE AND ACCOUNTING REQUIREMENTS AND WE MAY NOT BE ABLE TO ABSORB SUCH COSTS.** We may incur significant costs associated with our public company reporting requirements, costs associated with newly applicable corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the Securities and Exchange Commission. We expect these costs to approximate $50,000 per year, consisting of $30,000 in legal, $50,000 in audit and $10,000 for EDGAR filing and transfer agent fees. We expect all of these applicable rules and regulations to significantly increase our legal and financial compliance costs and to make some activities more time consuming and costly. We may not be able to cover these costs from our operations and may need to raise or borrow additional funds. We also expect that these applicable rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these newly applicable rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. In addition, we may not be able to absorb these costs of being a public company which will negatively affect our business operations.

**OUR OFFICERS AND DIRECTORS MAY HAVE A CONFLICT OF INTEREST WITH THE MINORITY SHAREHOLDERS AT SOME TIME IN THE FUTURE. SINCE THE MAJORITY OF OUR SHARES OF COMMON STOCK ARE OWNED BY OUR OFFICERS AND DIRECTORS AND A KEY CONSULTANT, OUR OTHER STOCKHOLDERS MAY NOT BE ABLE TO INFLUENCE CONTROL OF THE COMPANY OR DECISION MAKING BY MANAGEMENT OF THE COMPANY.** Our Officers and Directors beneficially own approximately 35% of our outstanding common stock. The interests of our Officers and Directors may not be, at all times, the same as that of our other shareholders. Our Officers and Directors are not simply passive investors but are also executives of the Company, their interests as executives may, at times be averse to those of passive investors. Where those conflicts exist, our shareholders will be dependent upon our directors exercising, in a manner fair to all of our shareholders, their fiduciary duties as officers or as member of the Company’s Board of Directors. Also, our directors will have the ability to control the outcome of most corporate actions requiring shareholder approval, including the sale of all or substantially all of our assets and amendments to our articles of incorporation. This concentration of ownership may also have the effect of delaying, deferring or preventing a change of control of us, which may be disadvantageous to minority shareholders.

**BECAUSE OUR OFFICERS AND DIRECTORS MAY IN FUTURE HAVE OUTSIDE BUSINESS ACTIVITIES, THERE IS A POTENTIAL CONFLICT OF INTEREST, INCLUDING THE AMOUNT OF TIME THEY WILL BE ABLE TO DEDICATE TO THE COMPANY.** Currently our officers, who are also directors, have been working on promoting business for the Company. A potential conflict of interest may arise in the future that may cause our business to fail, including conflicts of interest in allocating their time to our company and their other business interests. While our officers have verbally agreed to devote sufficient time and attention to the affairs of the Company, we have no written arrangement with our officers regarding this matter. As a result, we may face conflicts between business decisions that they may have to make regarding our operations and that of their other business interests.

18

#### Table of Contents

**BECAUSE OUR MANAGEMENT DOES NOT HAVE PRIOR EXPERIENCE RUNNING A PUBLIC COMPANY, WE MAY HAVE TO HIRE INDIVIDUALS OR SUSPEND OR CEASE OPERATIONS.** Because our management has limited prior experience in running a public company, including the preparation of reports under the Securities Act of 1934, we may have to hire additional experienced personnel to assist us with the preparation thereof. If we need the additional experienced personnel and we do not hire them, we could fail in our plan of operations and have to suspend operations or cease operations entirely.

**INDEPENDENT AUDIT COMMITTEE.** Although the common stock is not listed on any national securities exchange, for purposes of independence we use the definition of independence applied by NASDAQ. Currently, BGLC has three independent directors and they served as audit committee members. They are considered to be “independent” in accordance with the requirements set forth in NASDAQ Listing Rule 5605(a)(2). An independent audit committee plays a crucial role in the corporate governance process, assessing our Company’s processes relating to our risks and control environment, overseeing financial reporting, and evaluating internal and independent audit processes.

**POTENTIAL DATA BREACHES.** If we are successful, our services will generate and process a large quantity of personal health condition data. We face risks inherent in handling large volumes of data and in protecting the security of such data. In particular, we face a number of challenges relating to data inter-connected with regional labs, including:

- protecting the data in and hosted on our system, including against hacking on our system by outside parties or our employees;
- addressing concerns related to privacy and sharing, safety, security and others;
- complying with applicable laws, rules and regulations relating to the collection, use, disclosure of personal information, including any requests from regulatory and government authorities relating to such data;
- Any systems failure or security breach or lapse those results in the release of user data could harm our reputation and brand and, consequently, our business, in addition to exposing us to potential legal liability.

As we expand our operations, we may be subject to these laws in other jurisdictions where our customers and other participants are located. The laws, rules and regulations of other jurisdictions may impose more stringent or conflicting requirements and penalties than those in Malaysia, compliance with which could require significant resources and costs. Our privacy policies and practices concerning the collection, use and disclosure of user data are posted on our websites. Any failure, or perceived failure, by us to comply with our posted privacy policies or with any regulatory requirements or privacy protection-related laws, rules and regulations could result in proceedings or actions against us by authorities or others. These proceedings or actions may subject us to significant penalties and negative publicity, require us to change our business practices, increase our costs and severely disrupt our business.

19

#### Table of Contents

**CROSS-BORDER OPERATIONS.** As we plan to continue expanding our existing cross-border operations into existing and other markets, we will face risks associated with expanding into markets in which we have limited or no experience and in which our company may be less well-known. We may be unable to attract a sufficient number of customers and other participants, fail to anticipate competitive conditions or face difficulties in operating effectively in these new markets. The expansion of our cross-border business will also expose us to risks relating to staffing and managing cross-border operations, increased costs to protect intellectual property, tariffs and other trade barriers, differing and potentially adverse tax consequences, increased and conflicting regulatory compliance requirements, lack of acceptance of our service offerings, challenges caused by distance, language and cultural differences, exchange rate risk and political instability. Accordingly, any efforts we make to expand our cross-border operations may not be successful, which could limit our ability to grow our revenue, net income and profitability.

**RISKS RELATED TO DOING BUSINESS IN ASIA PACIFIC REGION.** Changes in the political and economic policies of the local government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies. Accordingly, our financial condition and results of operations are affected to a significant extent by economic, political and legal developments in Asia Pacific region.

The Asia Pacific economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. In addition, the government continues to play a significant role in regulating industry development by imposing industrial policies. The government also exercises significant control over economic growth by allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies.

The local government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall economy, but may also have a negative effect on us. Our financial condition and results of operation could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us. In addition, the government has implemented in the past certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity, which in turn could lead to a reduction in demand for our services and consequently have a material adverse effect on our businesses, financial condition and results of operations.

**YOU MAY EXPERIENCE DIFFICULTIES IN EFFECTING SERVICE OF LEGAL PROCESS, ENFORCING FOREIGN JUDGMENTS OR BRINGING ORIGINAL ACTIONS IN MALAYSIA BASED ON UNITED STATES OR OTHER FOREIGN LAWS AGAINST US OR OUR MANAGEMENT.** Our operating subsidiary is incorporated in Malaysia and conducts substantially all of our operations in Asia Pacific. All of our executive officers and directors reside outside the United States and all of their assets are located outside of the United States. As a result, it may be difficult or impossible for shareholders to bring an action against us or against these individuals in Malaysia in the event that you believe that your rights have been infringed under the securities laws of the United States or otherwise. Even if you are successful in bringing an action of this kind, the laws of Malaysia may render you unable to enforce a judgment against our assets or the assets of our directors and officers. There is no statutory recognition in Malaysia of judgments obtained in the United States, although the courts of Malaysia will generally recognize and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits. The rights of shareholders to take legal action against us and our directors, actions by minority shareholders and the fiduciary responsibilities of our directors are to a large extent governed by the common law of Malaysia. The common law of Malaysia is derived in part from comparatively limited judicial precedent in Malaysia as well as from English common law, which provides persuasive, but not binding, authority in a court in Malaysia. The rights of our shareholders and the fiduciary responsibilities of our directors under Malaysian law are not as clearly established as they would be under statutes or judicial precedents in the United States. In particular, Malaysia has a less developed body of securities laws than the United States and provides significantly less protection to investors. As a result, our public shareholders may have more difficulty in protecting their interests through actions against us, our management, our directors or our major shareholders than would shareholders of a corporation incorporated in a jurisdiction in the United States.

20

#### Table of Contents

### Risks Related to Our Common Stock

***SALES OF OUR COMMON STOCK IN RELIANCE ON RULE 144 MAY REDUCE PRICES IN THAT MARKET BY A MATERIAL AMOUNT.*** A significant number of the outstanding shares of our common stock are “restricted securities” within the meaning of Rule 144 under the Securities Act. As restricted securities, those shares may be resold only pursuant to an effective registration statement or pursuant to the requirements of Rule 144 or other applicable exemptions from registration under the Securities Act and as required under applicable state securities laws. Rule 144 provides in essence that an affiliate (*i.e.*, an officer, director or control person) who has held restricted securities for a prescribed period may, under certain conditions, sell every three months, in brokerage transactions, a number of shares that does not exceed 1.0% of the issuer’s outstanding common stock. The alternative limitation on the number of shares that may be sold by an affiliate, which is related to the average weekly trading volume during the four calendar weeks prior to the sale is not available to stockholders of companies whose securities are not traded on an “automated quotation system”; because the OTC-QB Market is not such a system, market-based volume limitations are not available for holders of our securities selling under Rule 144.

Pursuant to the provisions of Rule 144, there is no limit on the number of restricted securities that may be sold by a non-affiliate (*i.e*., a stockholder who has not been an officer, director or control person for at least 90 consecutive days before the date of the proposed sale) after the restricted securities have been held by the owner for a prescribed period, although there may be other limitations and/or criteria to satisfy. A sale pursuant to Rule 144 or pursuant to any other exemption from the Securities Act, if available, or pursuant to registration of shares of our common stock held by our stockholders, may reduce the price of our common stock in any market that may develop.

**YOU MAY NOT BE ABLE TO LIQUIDATE YOUR INVESTMENT SINCE THERE IS NO ASSURANCE THAT A PUBLIC MARKET WILL DEVELOP FOR OUR COMMON STOCK OR THAT OUR COMMON STOCK WILL EVER BE APPROVED FOR TRADING ON A RECOGNIZED EXCHANGE.** There is no established public trading market for our securities. Although we intend to be quoted on the OTC-QB Market in the United States, our shares are not and have not been quoted on any exchange or quotation system. We cannot assure you that a market maker will agree to file the necessary documents with the FINRA, nor can there be any assurance that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate its investment, which will result in the loss of your investment.

**OUR COMMON STOCK IS SUBJECT TO THE “PENNY STOCK” RULES OF THE SEC AND THE TRADING MARKET IN OUR SECURITIES IS LIMITED, WHICH MAKES TRANSACTIONS IN OUR STOCK CUMBERSOME AND MAY REDUCE THE VALUE OF AN INVESTMENT IN OUR STOCK.** Under U.S. federal securities legislation, our common stock will constitute “penny stock”. Penny stock is any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a potential investor’s account for transactions in penny stocks, and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve an investor’s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the Commission relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination. Brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock. Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

21

#### Table of Contents

**IN THE FUTURE, WE MAY ISSUE ADDITIONAL COMMON AND PREFERRED SHARES, WHICH WOULD REDUCE INVESTORS’ PERCENT OF OWNERSHIP AND MAY DILUTE OUR SHARE VALUE.** Our Articles of Incorporation authorize the issuance of 300,000,000 shares of common stock. As of the date of this filing, the Company had 171,218,152 shares of common stock outstanding. Accordingly, we may issue up to an additional 128,781,848 shares of common stock. In addition, we have the right to issue 30,000,000 shares of preferred stock. The preferred stock is known as “blank check” as the Board of Directors is authorized to set the rights, privileges and preference of the preferred stock. The future issuance of common stock and preferred may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock or preferred stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors, and might have an adverse effect on any trading market for our common stock.

**UPON EFFECTIVENESS OF THIS REGISTRATION STATEMENT, WE WILL NOT BE A FULLY REPORTING COMPANY UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934, RATHER WE WILL BE SUBJECT TO THE REPORTING REQUIREMENTS OF SECTION 15(D) OF THE EXCHANGE ACT WHICH IS LESS RESTRICTIVE ON US AND OUR INSIDERS.** In order for us to become a fully reporting company under Section 12(g) of the Exchange Act, we will have to file a Registration Statement on Form 8-A. If we do not become subject to Section 12 of the Exchange Act, we will be subject to Section 15(d) of the Exchange Act, and as such we will not be required to comply with (i) the proxy statement requirements which means shareholders may have less notice of pending matters, and (ii) the Williams Act which requires disclosure of persons or groups that acquire 5% of a company’s publicly traded stock and also regulates tender offers. In addition, our officer, director and 10% stockholder will not be required to submit reports to the SEC on their stock ownership and stock trading activity. These reports include Form 3, 4 and 5. Therefore, as a shareholder, less information and disclosure concerning these matters will be available to you.

**WE DO NOT INTEND TO PAY ANY CASH DIVIDENDS ON OUR COMMON STOCK, OUR STOCKHOLDERS WILL NOT BE ABLE TO RECEIVE A RETURN ON THEIR SHARES UNLESS THEY SELL THEM.** We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance that stockholders will be able to sell shares when desired.

**OUR COMMON STOCK PRICE IS LIKELY TO BE HIGHLY VOLATILE WHICH MAY SUBJECT US TO SECURITIES LITIGATION THEREBY DIVERTING OUR RESOURCES WHICH MAY AFFECT OUR PROFITABILITY AND RESULTS OF OPERATION.** The market price for our common stock is likely to be highly volatile as the stock market in general and the market for Internet-related stocks.

The following factors will add to our common stock price’s volatility:

- fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;
- changes in estimates of our financial results or recommendations by securities analysts;
- changes in market valuations of similar companies;

22

#### Table of Contents

- changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
- regulatory developments in Malaysia or other countries wherein we expect to conduct business;
- litigation involving our company, our general industry or both;
- investors’ general perception of us; and
- changes in general economic, industry and market conditions.

Many of these factors are beyond our control. These factors may decrease the market price of our common stock, regardless of our operating performance. In the past, plaintiffs have initiated securities class action litigation against a company following periods of volatility in the market price of its securities. In the future, we may be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

**REDUCED DISCLOSURE REQUIREMENTS APPLICABLE TO EMERGING GROWTH COMPANIES MAY MAKE OUR COMMON STOCK LESS ATTRACTIVE TO INVESTORS.** We qualify as an “emerging growth company” under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

- have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;
- comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);
- submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and
- disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We will remain an emerging growth company for up to five full fiscal years, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any January 31 before that time, we would cease to be an emerging growth company as of the following December 31, or if our annual revenues exceed $1 billion, we would cease to be an emerging growth company the following fiscal year, or if we issue more than $1 billion in non-convertible debt in a three-year period, we would cease to be an emerging growth company immediately.

Notwithstanding the above, we are also currently a “smaller reporting company,” meaning that we are not an investment company, an asset-backed issuer, nor a majority-owned subsidiary of a parent company that is not a smaller reporting company, and has a public float of less than $75 million and annual revenues of less than $50 million during the most recently completed fiscal year. If we are still considered a “smaller reporting company” at such time as we cease to be an “emerging growth company,” we will be subject to increased disclosure requirements. However, the disclosure requirements will still be less than they would be if we were not considered either an “emerging growth company” or a “smaller reporting company.” Specifically, similar to “emerging growth companies”, “smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting; are not required to conduct say-on-pay and frequency votes until annual meetings occurring on or after January 21, 2015; and have certain other decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in its SEC filings due to its status as an “emerging growth company” or “smaller reporting company” may make us less attractive to investors given that it will be harder for investors to analyze the Company’s results of operations and financial prospects and, as a result, it may be difficult for us to raise additional capital as and when we need it.

23

#### Table of Contents

## Properties

As filed, 1,689 characters.

Our corporate offices and the offices of BioNexus Malaysia are located at Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia. The lease commenced in December 15, 2020 and terminates in December 15, 2023. The space consists of 1,300 square feet with an annual rent of approximately $13,200 USD.

Our laboratory is located at Lab 353, University Science Malaysia, George Town, Penang, Malaysia. The lease commenced on May 2017 and terminates on April 2023. The space consists of 1,500 square feet with an annual rent of approximately $8,400 USD.

We also have a blood collection center located on 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. As mentioned above, Lifecare Medical Centre refers their patients to us and as a result, they have allowed to maintain a blood collection center on their premises on a rent-free basis.

Chemrex’s office and wholesale distribution center is located at 4, Jalan CJ 1/6, Kawasan Perusahaan Cheras Jaya, 43200 Cheras, Selangor, Malaysia. The space consists of 25,000 square feet. Chemrex is the owner of the premises.

Chemrex also maintains two investment properties;

1\. A condominium located at No. B-17-03, Duet Residence, Jalan Kinrara 6, Bandar Kinrara, 47180 Puchong, Selangor. The premises is 1,100 square feet and is leased to a third party at a rate of $488 per month. The lease is for 2 years terminating on February 2022.

2\. A commercial building located at First floor, No. 2B Pelangi Avenue, Jalan Kelicap 42A/KU1, Klang Bandar, Diraja, 41050 Klang, Selangor. The premises is 2,000 square feet and is not leased as of the date of this filing.

## Legal proceedings

As filed, 444 characters.

There are presently no pending legal proceedings to which the Company or any of its property is subject, or any material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class of voting securities is a party or has a material interest adverse to the Company, and no such proceedings are known to the Company to be threatened or contemplated against it.

## Management's discussion and analysis

As filed, 37,269 characters.

General.

*Our Company was incorporated on April 5, 2017 and operations of our Malaysian company began operations in July 2017. Consequently, the following discussion and analysis of the results of operations and financial condition of the Company is for fiscal years ended December 31, 2021 and December 31, 2020, respectively. This information should be read in conjunction with the notes to the financial statements that are included elsewhere herein. The consolidated financial statements presented herein (and to which this discussion relates) reflect the results of operations of the Company and its Malaysian subsidiaries. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.*

### COMPANY OVERVIEW

*Our financial statements are prepared in US Dollars and in accordance with accounting principles generally accepted in the United States. See information immediately below for information concerning the exchange rates at the Malaysian translated into US Dollars (“USD”) at various pertinent dates and for pertinent periods.*

Translation of amounts from the local currency of the Company into US$1 has been made at the following exchange rates for the respective years:

|  | As of and for the year ended December 31, 2021 | 2020 |
| --- | ---: | ---: |
| Year-end MYR : US$1 exchange rate | 4.1650 | 4.0170 |
| Yearly average MYR : US$1 exchange rate | 4.1456 | 4.2010 |

26

#### Table of Contents

### Summary of Business

We have two operating subsidiaries located in Malaysia, Bionexus Gene Lab Sdn. Bhd. (“Bionexus Malaysia”) and Chemrex Corporation Sdn. Bhd. (“Chemrex”).

BioNexus Malaysia is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, we acquired all of the outstanding capital stock of BioNexus Malaysia, which was incorporated in Malaysia on April 7, 2015. BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which we use in our business.

Our principal office address is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 122126512 and web-site is www.bionexusgenelab.com.

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate offices and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and web-site is www.chemrex.com.my.

Our corporate structure is depicted below:

The corporate structure as at December 31, 2021 is depicted below:

|  |  |
| --- | --- |
| BioNexus Gene Lab Corp. a Wyoming company |  |
| 100% owned | 100% owned |
| Bionexus Gene Lab Sdn. Bhd., a Malaysian company | Chemrex Corporation Sdn. Bhd., a Malaysian Company |

**Recent Events.**

#### Collaboration with Malaysia’s National Heart Institute

On August 1, 2020, our wholly owned Malaysian subsidiary, Bionexus Gene Lab Sdn Bhd (“BioNexus Malaysia”), entered into an Agreement for The Development Blood-Based Genomic Signatures in Acute Myocardial Infarction Risk Prediction Research Proposal with National Heart Centre (“NHI”) and Dato Dr. Amin Ariff Bin Nuruddin (“Principal Investigator”) (“Development Agreement”).

27

#### Table of Contents

The NHI is a Malaysian private limited company operating the business of Institut Jantung Negara, Malaysia’s National Heart Institute. NHI is the national referral center for acute myocardial infraction diseases (“AMI”) which provide diagnostic, medical and surgical services. NHI is under the direction of the Malaysian Ministry of Health. The Principal Investigator is an employee of the Institution and he is an experienced head of cardiologist and an interventionist of NHI.

Pursuant to the Development Agreement, the Institute and NHI, through the Principal Investigator, have agreed to collaborate in a research project with BioNexus Malaysia to provide information for purposes of utilizing and further developing our RNA technology. Blood samples will be collected from consenting AMI patients within two hours of being admitted to the NHI and prior to the administering any medication, so as to provide a true picture of the changes in the patient’s RNA by the microarray process. The blood samples will be provided to our lab where the RNA will be extracted for analysis. Similar to our other disease analysis process, the isolated RNA will be hybridized, probe array washed and stained and array scanned. We will then use the data from the research project to create a gene expression profile for the likelihood of an AMI event in patients using our RNA analysis. We expect to develop a gene panel from this project within the next 3 to 6 months.

Among other terms and conditions, the research project has been extended beyond on March 31, 2022 and BioNexus Malaysia is required to pay the approximately $1,100 per month in fees to NHI for the usage of its freezer and allowance for nurses and doctors who are required to explain to each participating patient about the research, his consent and patient consultation on the blood- based gene expression report for each patient.

During 2021, we have spent substantial time and effort on planning and preparing documentation for the Institute’s Ethics Committee review and approval such as establishing the objectives and benefits of the research and process protocols and other procedural items. Following the successful conclusion of the study by 3rd quarter of 2022, we are hopeful that NHI will take the lead to incorporate our RNA screening into their regular screening processes for patients. Industry information from the Institute indicates that Malaysians are developing heart disease at a younger age compared with their peers in other countries.

RESULTS OF OPERATIONS

**Results of Operations for the Year Ended December 31, 2021 Compared to the Year Ended December 31, 2020 (Audited).**

The following table sets forth key components of the results of operations for fiscal year ended December 31, 2021 and 2020, respectively. As stated herein, on December 31, 2021, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company and Chemrex and the Chemrex shareholders. Accordingly, the audited financial information for the period ended December 31, 2021 includes the accounts of Chemrex and BioNexus Malaysia and the (audited) financial information for the period ended December 31, 2020 only includes the accounts of BioNexus Malaysia.

28

#### Table of Contents

The discussion following the table addresses these results.

| Consolidated | Year ended December 31 (Audited) 2021 | 2020 |
| --- | ---: | ---: |
| REVENUE | $13,362,567 | $11,390,440 |
| COST OF REVENUE | (11,168,747) | (9,670,617) |
| GROSS PROFIT | 2,193,820 | 1,719,823 |
| OTHER INCOME | 66,491 | 886,942 |
| OPERATING EXPENSES |  |  |
| General and administrative | (1,204,484) | (1,332,943) |
| **PROFIT FROM OPERATIONS** | **1,055,827** | **1,273,822** |
| FINANCE COSTS | (12,973) | (11,313) |
| **PROFIT BEFORE TAX** | **1,042,854** | **1,262,509** |
| Tax expense: |  |  |
| Deferred tax | (26,736) | 1,238 |
| Income tax | (264,547) | (169,649) |
| Total tax expenses | (291,283) | (168,411) |
| **NET PROFIT** | **$751,571** | $1,094,098 |
| Other comprehensive income: |  |  |
| Foreign currency translation (loss)/gain | (233,946) | 150,787 |
| **COMPREHENSIVE INCOME** | **$517,625** | $1,244,885 |

*Revenues*. For the annual period ended December 31, 2021, we had revenues of $13,362,567 as compared to revenues of $11,390,440 for the annual period ended December 31, 2020, an increase of approximately 17.3% from the prior period due to qPCR screening on Covid-19 50,000 samples outsourced by public hospitals and clinics

*Cost of revenues*. For the annual period ended December 31, 2021 we had cost of revenues of $11,168,747 as compared to cost of revenues of $9,670,617 for the annual period ended December 31, 2020, an increase of approximately 15.5% from the prior period due to increase cost from qPCR kits and reagents purchases.

*Other Income*. For the annual period ended December 31, 2021, we had other income of $66,491 as compared to other income of $886,942 for the annual period ended December 31, 2020, a decrease of 92.5% for current year. The decrease in other income for the current annual period is due last year primarily Chemrex’s disposal of property which resulted in income of $706,953.

*Operating Expenses*. For the annual period ended December 31, 2021, we had operating expenses of $1,204,484, as compared to operating expenses of $1,332,943 for the annual period ended December 31, 2020, a decrease of 9.6% for the current year. Operating expenses include depreciation of fixed assets, equipment maintenance expenses, transportation, employee compensation and benefits, professional fees and marketing and travel expenses.

29

#### Table of Contents

*Profit/(loss) from operations*. We had a profit from operations of $1,055,827 for the annual period ended December 31, 2021 compared to a profit from operations of $1,273,822 for the annual period ended December 31, 2020, a decrease of 17.1% for the reasons discussed above.

*Tax expense*. For the year ended December 31, 2021, we had a total tax expense of $291,283 from deferred tax of $26,736 and income tax provision of $264,547. Last year ended December 31, 2020 the total tax expenses were $168,411 from an adjustment for over provision of deferred tax liabilities in prior year for credit amount of $1,238 and income tax provision of $169,649.

*Foreign currency translation (loss)/gain*. We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate will require us to recognize a transaction gain or loss on revaluation. For the annual period ended December 31, 2021, we had foreign currency translation loss of $233,946 compared with foreign currency translation gain $150,787 for the prior annual period.

### BioNexus-Malaysia and Chemrex

|  | BioNexus Malaysia Year ended December 31, 2021 | Chemrex | BioNexus Malaysia Year ended December 31, 2020 | Chemrex |
| --- | ---: | ---: | ---: | ---: |
| REVENUE | $1,515,673 | $11,846,894 | $134,095 | $11,256,345 |
| COST OF REVENUE | (1,126,059) | (10,042,688) | (113,042) | (9,557,576) |
| GROSS PROFIT | 389,614 | 1,804,206 | 21,053 | 1,698,769 |
| OTHER INCOME | 7,467 | 59,024 | 13,148 | 873,793 |
| OPERATING EXPENSES |  |  |  |  |
| General and administrative | (86,973) | (989,617) | (88,789) | (1,107,002) |
| FINANCE COSTS | (4,158) | (8,815) | (2,482) | (8,831) |
| **PROFIT/(LOSS) BEFORE TAX** | **305,950** | **864,798** | **(57,070)** | **1,456,729** |
| Tax expense : |  |  |  |  |
| Deferred tax | (11,997) | (14,739) | - | 1,238 |
| Income tax | (30,482) | (234,065) | (881) | (168,768) |
| Total tax expense | (42,479) | (248,804) | (881) | (167,530) |
| **NET PROFIT/(LOSS)** | **$263,471** | **$615,994** | **$(57,951)** | **$1,289,199** |

*Revenue.* For the annual period ended December 31, 2021, Chemrex contributed $11,846,894 (88.66%) of total combined revenue of $13,362,567 compared to its contribution of $11,256,345 (98.82%) of total combined revenue of $11,390,440 for the same period last year, an increase of 17.31% on the total combined revenues from both subsidiaries. The increase was due the material selling prices have been increased by Chemrex and the government outsourcing Covid’ qPCR screening to Bionexus Malaysia in 2021.

BioNexus had a revenue of $1,515,673 (11.34%) for the current year compared to revenues of $134,095 (1.18%) from the last year, an increase of 1,030.30%. BioNexus revenues for the current year resulted from the outsource of Covid19 PCR test from Health Ministry which began on May 2021 for contract value of $549,133 which had been completed in July 2021 and an additional contract in July, 2021 for contract value of $859,804 which had been completed as of Dec 31, 2021

*Cost of revenues*. For the annual period ended December 31, 2021, Chemrex had incurred $10,042,688 (89.92%) of the total combined cost of revenue of $11,168,747 as compared to the same period last year wherein Chemrex had incurred $9,557,576 (98.83%) of the total combined cost of revenue of $9,670,617. The increase of 5.08% in Chemrex’s cost of revenues for the current year was due to its increased revenues for the current period and reasons as stated above.

BioNexus had incurred $1,126,059 (10.08%) on cost of revenues for the current year as compared to cost of revenues of $113,042 (1.17%) for the same period last year. The increase of 896% in cost of revenue for the current period reflects the costs associated with the outsource of Covid19 PCR test from the Health Ministry which began in May 2021 till December 2021.

30

#### Table of Contents

*Other Income*. For the annual period ended December 31, 2021, Chemrex contributed $59,024 (88.77%) of total other combined income of $66,491 as compared to the last year period $873,793 (98.52%). A reduction of 93.25% from the prior year is due principally the net income of $707,618 from disposal of a property which occurred during financial year 2020. We did not have a similar gain during the current year.

BioNexus had other income of $7,467 (11.23%) for current year as compared $13,148 (1.48%) for the last year, a decrease of 43.21% for current year due to reduced bank interest rate.

*Operating Expenses*. For the annual period ended December 31, 2021, Chemrex had incurred $989,617 (91.92%) of the total combined operating expenses of $1,076,590 for the current annual period in 2021 as compared to the operating expenses of $1,107,002 (92.57%) for the same period last year. The decrease of 10.60% in Chemrex operating expenses for the current period due to major expenses reduced were the commission payout to property agent and website development fee which had been completed

BioNexus Malaysia had incurred $86,973 (8.08%) on operating expenses during for the current annual period in 2021 as compared to the operating expenses of $88,789 (7.43%) for the same period last year, a decrease of 2.05% for current year. Due to a $9,890 write-off on an investment in Genenews Diagnostics Sdn. Bhd,

*Profit from Operations*. Chemrex had a profit from operations of $864,798 (73.87%) during the current annual period in 2021 compared to a profit from operations of $1,456,729 while Bionexus Malaysia incurred a loss of $57,070 for the same period in 2020, for the reasons discussed above. In addition, during last year 2020 period, Chemrex had one-time property disposal gain of $742,487.

*Income tax expense*. Chemrex had tax provision of $234,065 and deferred tax of $14,739, total tax expense of $248,804 (85.42%) for current year ended December 31, 2021 as compared to total tax expense of $167,530 for the last year ended December 31, 2020 from deferred tax credit of $1,238 and tax provision of $168,768.

BioNexus Malaysia had tax provision of $30,482 and deferred tax of $11,997, total tax expense of $42,479 (14.58%) for current year 2021 as compared with $881 for the last year ended December 31, 2020.

31

#### Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2021, we had working capital of $4,821,100 compared with working capital of $4,611,896 as of December 31, 2020. The increased in working capital as of December 31, 2021 from December 31, 2020 is due principally to the operating profit the Company experienced for the current year end period.

Our primary uses of cash have been for operations. The main sources of cash have been from operational revenues and the private placement of our common stock. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:

- Addition of administrative and marketing personnel as the business grows,
- Development of a Company website,
- Increases in advertising and marketing in order to attempt to generate more revenues, and
- The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows provided by (used in) / generated from operating, investing, and financing activities for the year ended December 31, 2021 and 2020:

|  | Year ended December 31, 2021 | 2020 |
| --- | ---: | ---: |
| Net Cash generated from Operating Activities | $9,161 | $552,680 |
| Net cash (used in) /generated from investing activities | (490,574) | 1,319,990 |
| Net cash used in generated from financing activities | (28,222) | (4,947) |
| Foreign currency translation adjustment | (154,138) | 60,893 |
| **Net Change in Cash and Cash Equivalents** | $(663,773) | $1,928,616 |

#### Operating Activities

During the year ended December 31, 2021, the Company incurred a net profit of 751,571 which, after adjusting for amortization, depreciation, dividend income, fair value on investment, an increase in inventories, trade receivables and deposits, a substantial reduction in trade payables, operating lease liabilities, resulted in net cash of $9,161 being generated from operating activities during the period. By comparison, during the year ended December 31, 2020, the Company had a net profit of $1,094,098 which, after adjusting for amortization, depreciation, dividend income, gain on disposal of property, plant and equipment $701,447, a decrease in inventories, a reduce in receivables and deposits, a substantial reduction in trade payables, operating lease liabilities, resulted in net cash of $552,680 being generated from operating activities during the period.

#### Investing Activities

During the year ended December 31, 2021, the Company had net cash of $490,574 used in investment activities. During the year ended December 31, 2020, the Company had net cash from acquisition of business under common control and disposed of property, plant and equipment of $1,467,865, resulting in net cash generated from investment activities of $1,319,990

#### Financing Activities

During the year ended December 31, 2021, Company continued the repayment of a finance lease resulting in net cash used in financing activities of $28,222. By comparison, during the year ended December 31, 2020, we had financing activities of $4,947 due to 6 months moratorium on leasing and loan instalments as initiated by the Malaysian Prime Minister in order to lessen the hardship faced by individual borrowers and Small and Medium Enterprises to enjoy an automatic monthly loan instalments moratorium for year, starting from April 1, 2020 till September 30, 2020

32

#### Table of Contents

### Summary of Significant Accounting Policies.

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

- Basis of presentation

These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

- Basis of consolidation

The consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

- Use of estimates

In preparing these financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.

- Cash and cash equivalents

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

33

#### Table of Contents

- Trade receivables

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

- Inventories

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Condensed Statements of Operations and Comprehensive Income.

- Leases

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases, which was subsequently amended in 2018 by ASU 2018-10, ASU 2018-11 and ASU 2018-20 (collectively, Topic 842). Topic 842 will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. Topic 842 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. Topic 842 allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods.

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1,2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

34

#### Table of Contents

- Property, Plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows:

| Categories | Principal Annual Rates/Expected Useful Life |
| --- | ---: |
| Air conditioner | 20% |
| Buildings | 2% |
| Computer and software | 33% |
| Equipment | 20% |
| Furniture and fittings | 10% to 20% |
| Lab Equipment | 10% |
| Motor vehicle | 10% to 20% |
| Office equipment | 20% |
| Renovation | 10% to 20% |
| Signboard | 10% |

Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

- Impairment of long-lived assets

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

35

#### Table of Contents

- Finance lease

Leases that transfer substantially all the rewards and risks of ownership to the lessee, other than legal title, are accounted for as finance leases. Substantially all of the risks or benefits of ownership are deemed to have been transferred if any one of the four criteria is met: (i) transfer of ownership to the lessee at the end of the lease term, (ii) the lease containing a bargain purchase option, (iii) the lease term exceeding 75% of the estimated economic life of the leased asset, (iv) the present value of the minimum lease payments exceeding 90% of the fair value. At the inception of a finance lease, the Company as the lessee records an asset and an obligation at an amount equal to the present value of the minimum lease payments. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company. The periodic rent payments made during the lease term are allocated between a reduction in the obligation and interest element using the effective interest method in accordance with the provisions of ASC Topic 835-30, “Imputation of Interest”.

- Revenue recognition

Revenue recognized when it is probable that the economic benefits associated with the transaction will flow to the enterprise and the amount of the revenue can be measured reliably. Revenue is measured at the fair value of consideration received or receivable.

a. The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts, ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes

i. Identifying the contracts or agreements with a customer,

ii. Identifying our performance obligations in the contract or agreement,

iii. Determining the transaction price,

iv. Allocating the transaction price to the separate performance obligations, and

v. Recognizing revenue as each performance obligation is satisfied.

The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

b. Interest income

Interest is recognized on receipt basis.

- Cost of revenues

Cost of revenue includes the purchase cost of retail goods for re-sale to customers and packing materials (such as boxes). It excludes purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and other costs of distribution network in cost of revenues.

36

#### Table of Contents

- Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping ang handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

- Comprehensive income

ASC Topic 220, “*Comprehensive Income”* establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

- Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “*Income Taxes” (“*ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

- Net loss per share

The Company calculates net loss per share in accordance with ASC Topic 260 “*Earnings per share”*. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

- Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the Company maintains its books and record in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the entity operates.

37

#### Table of Contents

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “*Translation of Financial Statement”*, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income.

Translation of amounts from the local currency of the Company into US$1 has been made at the following exchange rates for the respective years:

|  | As of and for the year ended December 31, 2021 | 2020 |
| --- | ---: | ---: |
| Year-end MYR: US$1 exchange rate | 4.1650 | 4.0170 |
| Yearly average MYR: US$1 exchange rate | 4.1456 | 4.2010 |

- Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

- Fair value of financial instruments

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments.

The Company also follows the guidance of the ASC Topic 820-10, “*Fair Value Measurements and Disclosures” (“*ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

- *Level 1*: Observable inputs such as quoted prices in active markets;
- *Level 2*: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
- *Level 3*: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

As of December 31, 2021, and December 31, 2020, the Company did not have any non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

- Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

38

#### Table of Contents

## Controls and procedures

As filed, 6,545 characters.

#### Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this annual report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of December 31, 2021. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was not accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

#### Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

- Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;
- Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the board of directors; and
- Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

39

#### Table of Contents

The Company’s management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) as set forth in its Internal Control - Integrated Framework. This assessment identified material weaknesses in internal control over financial reporting. A material weakness is a control deficiency, or a combination of deficiencies in internal control over financial reporting that creates a reasonable possibility that a material misstatement in annual or interim financial statements will not be prevented or detected on a timely basis. Since the assessment of the effectiveness of our internal control over financial reporting did identify a material weakness, management considers its internal control over financial reporting to be ineffective.

Management has concluded that our internal control over financial reporting had the following material deficiencies:

- We were unable to maintain segregation of duties within our business operations due to our reliance on a single individual fulfilling the role of sole officer and director.
- Lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal control and procedures.

These control deficiencies to our 2020 or 2019 interim or annual financial statements could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties. Accordingly, we have determined that this control deficiency constitutes a material weakness.

To the extent reasonably possible, given our limited resources, our goal is, upon consummation of a merger with a private operating company, to separate the responsibilities of principal executive officer and principal financial officer, intending to rely on two or more individuals. We will also seek to expand our current board of directors to include additional individuals willing to perform directorial functions. Since the recited remedial actions will require that we hire or engage additional personnel, this material weakness may not be overcome in the near term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the advice of outside professionals and consultants.

This annual report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

### Changes in Internal Controls over Financial Reporting

During the year ended December 31, 2021, other than the change in ownership, there has been no change in internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Filed Apr 6, 2022.
Source: SEC EDGAR, the filing index for accession 0001477932-22-002089. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
